GlaxoSmithKline (GSK) has announced several changes intended to improve its transparency, Reuters reports. GSK will stop paying doctors for promoting its drugs; eliminate prescription targets for its marketing staff; and end payments to health care professionals to attend medical conferences. These changes may push the whole pharmaceuticals industry to address allegations of aggressive marketing tactics.

To read the article, click here.